Vimarsana
Biggest News Aggregation in the World

Page 38 - Clinical Practice News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Clinical Practice. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Clinical Practice Today - Breaking & Trending Today

Electronic Health Records Failed to Make Clinicians' Lives Easier—Will AI Technology Succeed? | Professional Well-being | JAMA - Vimarsana News

Electronic Health Records Failed to Make Clinicians' Lives Easier—Will AI Technology Succeed? | Professional Well-being | JAMA

In this Medical News article, medical informatics expert Kevin B. Johnson, MD, MS, of the University of Pennsylvania discusses whether artificial intelligence c

2 University of Pittsburgh gastroenterologists honored by AGA - Vimarsana News

2 University of Pittsburgh gastroenterologists honored by AGA

Robert Schoen, MD, and Dhiraj Yadav, MD, of the University of Pittsburgh School of Medicine have been awarded the 2024 Research Mentor Awards from the American Gastroenterological Association.

MUTUAL PARTNERSHIPS AT THE CENTRE OF ADDRESSING INCREASED MORAL DILEMMAS IN HEALTHCARE SETTINGS IN TANZANIA - Vimarsana News

MUTUAL PARTNERSHIPS AT THE CENTRE OF ADDRESSING INCREASED MORAL DILEMMAS IN HEALTHCARE SETTINGS IN TANZANIA

Mtanzania MUTUAL PARTNERSHIPS AT THE CENTRE OF ADDRESSING INCREASED MORAL DILEMMAS IN HEALTHCARE SETTINGS IN TANZANIA - Featured

Managing Adverse Events in Patients Undergoing Treatment for HR+/HER2- mBC - Vimarsana News

Managing Adverse Events in Patients Undergoing Treatment for HR+/HER2- mBC

Elizabeth Diaz, PA-C, details how she approaches adverse event management in patients undergoing treatment for HR+/HER2- metastatic breast cancer.

Selecting an Appropriate Treatment Regimen for Patients With HR+/HER2- mBC - Vimarsana News

Selecting an Appropriate Treatment Regimen for Patients With HR+/HER2- mBC

Dr Virginia Kaklamani explains how she selects among the available treatment regimens for her patients with HR+/HER2= metastatic breast cancer.